Integrated catecholamine imaging in heart and lung across different cardiopulmonary disorders: a systems-based pilot analysis

Background: Autonomic nervous system deregulation is key in the progression of different cardiovascular diseases, and scintigraphic imaging with metaiodobenzilguanidine (MIBG) is the gold-standard its non-invasive evaluation. While heart catecholamine handling has been more extensively evaluated, fewer data are available on lung or combined cardiopulmonary MIBG uptake. The aim of this short communication is the simultaneous analysis of cardiopulmonary MIBG uptake to improve patients' characterization.Methods: 126 subjects were retrospectively analyzed based on the underlying etiology (systolic heart failure-HF, n = 52; myocardial infarction -MI, n = 26; pulmonary arterial hypertension -PAH, n = 13; cardiac amyloidosis -CA, n = 14; candidates to transcatheter aortic valve replacement -pre-TAVI, n = 21). The cut-off values of 1.6 and 1.62 were chosen for cardiac and lung/mediastinum ratios, respectively.Results: Combined alterations of MIBG uptake were found in 37% of patients. In HF and MI, simultaneous cardiopulmonary derangement was found in 40 and 46% of the patients, respectively, while in CA up to 65% of patients showed combined cardiopulmonary alterations. Conversely, patients with PAH mainly showed lung-only involvement (54%) and pre-TAVI patients cardiac-only alterations (24%).Conclusions: Simultaneous cardiopulmonary alterations of catecholamines handling are highly prevalent and may help to better characterize concurrent end-organ dysfunction in different diseases.